CD133 Is a Useful Surrogate Marker for Predicting Chemosensitivity to Neoadjuvant Chemotherapy in Breast Cancer

BACKGROUND: Neoadjuvant chemotherapy (NAC) is a standard care regimen for patients with breast cancer. However, the pathologic complete response (pCR) rate remains at 30%. We hypothesized that a cancer stem cell marker may identify NAC-resistant patients, and evaluated CD133 and ALDH1 as a potential...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Aomatsu, Naoki, Yashiro, Masakazu, Kashiwagi, Shinichiro, Takashima, Tsutomu, Ishikawa, Tetsuro, Ohsawa, Masahiko, Wakasa, Kenichi, Hirakawa, Kosei
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Public Library of Science 2012
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3457956/
https://ncbi.nlm.nih.gov/pubmed/23049880
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0045865
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak